Search

Your search keyword '"Bibi, Sagida"' showing total 219 results

Search Constraints

Start Over You searched for: Author "Bibi, Sagida" Remove constraint Author: "Bibi, Sagida"
219 results on '"Bibi, Sagida"'

Search Results

2. A novel whole blood assay to quantify the release of T cell associated cytokines in response to Bordetella pertussis antigens

3. Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

4. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history

5. A multi-platform approach to identify a blood-based host protein signature for distinguishing between bacterial and viral infections in febrile children (PERFORM): a multi-cohort machine learning study

6. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

7. Relationship between molecular pathogen detection and clinical disease in febrile children across Europe: a multicentre, prospective observational study

8. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

9. Impact of infection on proteome-wide glycosylation revealed by distinct signatures for bacterial and viral pathogens

10. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses

11. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

12. Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19

13. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

14. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial

15. Divergent trajectories of antiviral memory after SARS-CoV-2 infection

16. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

17. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

18. Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussis

19. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

20. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

21. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

22. Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussis

23. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

24. Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination.

25. Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.

26. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

27. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

28. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

29. The formulation of artificial reference standards for use within the ELISPOT assay

30. Impact of infection on proteome-wide glycosylation revealed by distinct signatures for bacterial and viral pathogens

31. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses

32. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens

33. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens

34. Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

35. Omicron BA.1/BA.2 infections in triple-vaccinated individuals enhance a diverse repertoire of mucosal and blood immune responses

36. Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

37. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection

38. Constructing custom-made radiotranscriptomic signatures of vascular inflammation from routine CT angiograms: a prospective outcomes validation study in COVID-19

39. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

40. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

41. Febrile illness in high-risk children: a prospective, international observational study

42. An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

43. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

44. Evolution of long-term vaccine induced and hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study

45. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

46. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

47. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees

48. Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers

49. Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR

50. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Catalog

Books, media, physical & digital resources